Fist line chemotherapy in advanced ovarian cancer: a comparison of three therapeutic regimes.
The first line polichemotherapeutic regimens are compared (intracavitary Cyclophosphamide + CMF, ACy and PEC) in 47 patients with advanced ovarian carcinoma. The response was 56.4% for Ex-CMF (CR 39.1%), 76.8% for ACy (CR 61.5%) and 81.8% for PEC (CR 63.6%). The three-year survival was 39.1% with Ex-CMF, 53.8% with ACy and 72.7% (follow-up not yet completed) for PEC. Toxicity was modest in all the three therapeutic regimens.
Cherchi
P L
PL
Gynaecologic and Obstetric Institute, University of Sassari, Italy.
Bagella
M P
MP
Campiglio
A
A
Rubattu
A
A
Farina
M
M
Ambrosini
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
D015251:Epirubicin; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate